AAA
EPRX

Affinity Asset Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Affinity Asset Advisors’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5M Buy
1,589,005
+1,289,005
+430% +$10.4M 0.59% 43
2025
Q4 		$2.27M Hold
300,000
– – 0.13% 80
2025
Q3 		$1.77M Buy
+300,000
New +$1.63M 0.15% 78

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Affinity Asset Advisors's EPRX Position: Q1 2026 in Review

Affinity Asset Advisors increased its Eupraxia Pharmaceuticals (EPRX) stake by 430% in Q1 2026, buying an estimated $10.4M and bringing the position to 1,589,005 shares worth $11.5M. The position accounts for 0.59% of the portfolio, ranked #43.

Affinity Asset Advisors first reported a position in EPRX in Q3 2025 and has held it in 3 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Affinity Asset Advisors held 1,589,005 shares of Eupraxia Pharmaceuticals worth $11.5M as of Q1 2026.
  • Affinity Asset Advisors bought 1,289,005 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $10.4M.
  • Eupraxia Pharmaceuticals made up 0.59% of Affinity Asset Advisors's portfolio in Q1 2026, its #43 holding.
  • Affinity Asset Advisors first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.